CX Institutional’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.2M | Buy |
95,317
+2,323
| +2% | +$272K | 0.35% | 59 |
|
|
2026
Q1 | $11.2M | Sell |
92,994
-13,575
| -13% | -$1.57M | 0.34% | 63 |
|
|
2025
Q4 | $11.2M | Buy |
106,569
+9,768
| +10% | +$917K | 0.33% | 64 |
|
|
2025
Q3 | $8.13M | Sell |
96,801
-10,533
| -10% | -$868K | 0.25% | 97 |
|
|
2025
Q2 | $8.5M | Sell |
107,334
-18,031
| -14% | -$1.43M | 0.3% | 68 |
|
|
2025
Q1 | $11.3M | Buy |
125,365
+106,247
| +556% | +$9.92M | 0.42% | 56 |
|
|
2024
Q4 | $1.9M | Sell |
19,118
-12,203
| -39% | -$1.26M | 0.08% | 180 |
|
|
2024
Q3 | $3.56M | Sell |
31,321
-51,605
| -62% | -$6.13M | 0.16% | 165 |
|
|
2024
Q2 | $10.3M | Sell |
82,926
-1,994
| -2% | -$257K | 0.48% | 60 |
|
|
2024
Q1 | $11.2M | Buy |
84,920
+9,751
| +13% | +$1.2M | 0.54% | 51 |
|
|
2023
Q4 | $8.19M | Buy |
75,169
+12,641
| +20% | +$1.31M | 0.44% | 66 |
|
|
2023
Q3 | $6.44M | Buy |
62,528
+42,928
| +219% | +$4.63M | 0.35% | 75 |
|
|
2023
Q2 | $2.26M | Buy |
19,600
+610
| +3% | +$69.3K | 0.12% | 203 |
|
|
2023
Q1 | $2.05M | Sell |
18,990
-36,618
| -66% | -$3.95M | 0.11% | 215 |
|
|
2022
Q4 | $6.17M | Buy |
55,608
+5,553
| +11% | +$568K | 0.37% | 63 |
|
|
2022
Q3 | $4.31M | Buy |
50,055
+7,827
| +19% | +$699K | 0.3% | 90 |
|
|
2022
Q2 | $3.85M | Sell |
42,228
-2
| -0% | -$177 | 0.29% | 88 |
|
|
2022
Q1 | $3.46M | Sell |
42,230
-2,675
| -6% | -$211K | 0.28% | 103 |
|
|
2021
Q4 | $3.44M | Buy |
44,905
+13,848
| +45% | +$1.1M | 0.27% | 116 |
|
|
2021
Q3 | $2.33M | Buy |
31,057
+141
| +0.5% | +$10.7K | 0.19% | 126 |
|
|
2021
Q2 | $2.4M | Sell |
30,916
-22,283
| -42% | -$1.66M | 0.2% | 123 |
|
|
2021
Q1 | $3.91M | Buy |
53,199
+4,635
| +10% | +$342K | 0.35% | 84 |
|
|
2020
Q4 | $3.79M | Sell |
48,564
-151
| -0.3% | -$11.5K | 0.37% | 67 |
|
|
2020
Q3 | $3.86M | Buy |
48,715
+38,865
| +395% | +$3.04M | 0.42% | 64 |
|
|
2020
Q2 | $727K | Buy |
9,850
+1,601
| +19% | +$121K | 0.1% | 167 |
|
|
2020
Q1 | $606K | Buy |
8,249
+1,795
| +28% | +$141K | 0.1% | 160 |
|
|
2019
Q4 | $560K | Buy |
6,454
+12
| +0.2% | +$986 | 0.1% | 144 |
|
|
2019
Q3 | $517K | Buy |
6,442
+104
| +2% | +$8.34K | 0.08% | 164 |
|
|
2019
Q2 | $507K | Buy |
6,338
+715
| +13% | +$54.7K | 0.08% | 163 |
|
|
2019
Q1 | $446K | Buy |
5,623
+1,211
| +27% | +$90.6K | 0.08% | 163 |
|
|
2018
Q4 | $322K | Buy |
4,412
+4,351
| +7,133% | +$307K | 0.07% | 147 |
|
|
2018
Q3 | $4K | Hold |
61
| – | – | ﹤0.01% | 303 |
|
|
2018
Q2 | $4K | Buy |
+61
| New | +$3.44K | ﹤0.01% | 284 |
|
Other funds holding MRK
ATO
CX Institutional's MRK Position: Q2 2026 in Review
CX Institutional increased its Merck (MRK) stake by 2.5% in Q2 2026, buying an estimated $272K and bringing the position to 95,317 shares worth $12.2M. The position accounts for 0.35% of the portfolio, ranked #59.
CX Institutional first reported a position in MRK in Q2 2018 and has held it in 33 quarters since. 1,549 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- CX Institutional held 95,317 shares of Merck worth $12.2M as of Q2 2026.
- CX Institutional bought 2,323 Merck shares in Q2 2026, an estimated $272K.
- Merck made up 0.35% of CX Institutional's portfolio in Q2 2026, its #59 holding.
- CX Institutional first reported a position in Merck in Q2 2018 and has held it in 33 quarters since.
- 1,549 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.